Clinical Trial Search

Primary: Mean Change From Baseline in Pruritus Symptoms, as Measured by the 24-hour Average Pruritus Visual Analogue Scale (VAS) Score — -41.5; -35.8 score on a scale

Primary: Change From Baseline to Endpoint (Day 28 or Early Termination) in Visual Analogue Scale (VAS) Pruritus 24 Hour Average Intensity. — -40.5; -36.5 mm

Primary: Investigator Global Assessment- Atopic Dermatitis — 1.7; 1.5 units on a scale

Primary: Change in WI-NRS From Baseline to Week 6 — -2.25; -2.32; -2.01 score on a scale

Primary: Pruritus VAS Scores at Baseline, Week 2 and Week 4 — 7.8; 7.5; 6.10; 5.9 units on a scale

Primary: Change in Itch Intensity as Measured by a Change in Visual Analog Scale (VAS) Score — 0.8; -5.0 centimeters

Primary: Pruritus by VAS (Visual Analogue Scale) — 19.7; 21.2 mm — p=0.58

Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 24 — -58.4; -72.2; -73.4; -69.2 percentage change — p=0.051

Primary: Percentage of Participants With Greater Than or Equal to (>=) 4 Points Improvement (Reduction) From Baseline in Worst-Itch Numeric Rating Scale (WI-NRS) Scores at Week…

Primary: Percentage of Participants Who Had at Least a 2-grade Reduction From Baseline at Week 6 in the Investigator Global Assessment (IGA) Scale and Had an IGA at Week 6 That…

Primary: Change From Baseline in the m-EASI (Eczema Area Severity Index) Score. — 5.04; 4.77 units of a 0-12 scale — p=<0.05

Primary: Reduction of Itching in AD — 1.70; 1.55 score on a scale

Primary: Proportion of SCORAD-50 Response at Week 16. — 5; 3 Participants

Primary: Number of Allergen-induced Eosinophils in the Skin — 11.95; 71.15 cells/mm2

Primary: Worst Itch Numeric Rating Scale 4-point Responder Rate at Week 10 — 46; 44 Participants — p=0.5861

Primary: Percentage of Participants With Improvement (Reduction) in Worst Itch Numeric Rating Scale (WI-NRS) Scores by Greater Than or Equal to (>=) 4 Points From Baseline to…

Primary: Change in Pruritis Visual Analog Scale (VAS) — -12.4; -15.5; -13.9; -6.2 mm

Primary: Change From Baseline in Intraepidermal Nerve Fiber Density on Lesional Skin at Week 17 — 8.4567; 4.2618 F/mm^2

Primary: Percentage Change in SCORAD — -18.8; -11.7 percentage change

Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change

Primary: Change in Peak Pruritus Numerical Rating Score (PRNS) — -3.1 score on a scale

Primary: Percentage of Participants Who Had at Least a 2-grade Reduction From Baseline at Week 6 in the Investigator Global Assessment (IGA) Scale and Had an IGA at Week 6 That…

Primary: Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points — 2 participants

Primary: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4 — 32.0; 15.2 percentage of participants — p=<0.0001

Primary: Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT)…

Primary: Percent of Participants With Worst Itch Numeric Rating Scale (WI-NRS) 4-point Responder Rate at Week 10 — 18.95; 25.90; 81.05; 74.10 Percentage of participants — p=0.158

Primary: Mean Change in Worst Itch Numeric Rating Scale (WI-NRS) — -2.8; -2.8; -2.1 score on a scale — p=0.0148

Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Intent-To-Treat (ITT) Population — 37.7; 26.0 percentage of participants…

Primary: Percent of Subjects With Worst-Itch Numeric Rating Scale 4-point Responder at Week 10 — 26.45; 20.31 Percentage of subjects — p=0.229

Primary: Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (Placebo, 2 mg or 4 mg Baricitinib) — 17.2; 27.6; 31.5 percentage of participants — p=0.071